These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM. Marley SB; Davidson RJ; Goldman JM; Gordon MY Leukemia; 2000 Aug; 14(8):1396-400. PubMed ID: 10942234 [TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma. Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784 [TBL] [Abstract][Full Text] [Related]
5. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Issaad C; Vainchenker W Blood; 1994 Nov; 84(10):3447-56. PubMed ID: 7524739 [TBL] [Abstract][Full Text] [Related]
6. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors. Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928 [TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients. Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859 [TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Marley SB; Deininger MW; Davidson RJ; Goldman JM; Gordon MY Exp Hematol; 2000 May; 28(5):551-7. PubMed ID: 10812245 [TBL] [Abstract][Full Text] [Related]
9. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients. Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929 [TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia. Thijsen SF; van Oostveen JW; Schuurhuis GJ; Theijsmeijer AP; Oudejans CB; van Wijk IJ; Langenhuijsen MM; Ossenkoppele GJ Leukemia; 1997 Oct; 11(10):1762-8. PubMed ID: 9324298 [TBL] [Abstract][Full Text] [Related]
12. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. Savoldo B; Sammarelli G; Dotti G; Garau D; Regazzi E; Cilloni D; Tabilio A; Rizzoli V; Carlo-Stella C Leukemia; 1998 Mar; 12(3):434-40. PubMed ID: 9529140 [TBL] [Abstract][Full Text] [Related]
13. The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures. Robak T; Korycka A Leuk Lymphoma; 1996 Mar; 21(1-2):161-8. PubMed ID: 8907284 [TBL] [Abstract][Full Text] [Related]
14. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625 [TBL] [Abstract][Full Text] [Related]
15. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells. Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115 [TBL] [Abstract][Full Text] [Related]
16. A differential sensitivity to recombinant human interferon-alpha 2a between normal and chronic myeloid leukaemic peripheral blood granulocyte-macrophage colony-forming units. Gronthos S; To LB; Haylock DN; Juttner CA Leuk Res; 1992; 16(2):153-8. PubMed ID: 1545568 [TBL] [Abstract][Full Text] [Related]
17. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327 [TBL] [Abstract][Full Text] [Related]
18. Potent antileukemic activity of the novel agents norsegoline and dibezine. Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051 [TBL] [Abstract][Full Text] [Related]
19. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474 [TBL] [Abstract][Full Text] [Related]
20. All-trans-retinoic acid effects the growth, differentiation and apoptosis of normal human myeloid progenitors derived from purified CD34+ bone marrow cells. Douer D; Ramezani L; Parker J; Levine AM Leukemia; 2000 May; 14(5):874-81. PubMed ID: 10803520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]